NCT03307785 2025-11-25Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042Tesaro, Inc.Phase 1 Completed60 enrolled 91 charts
NCT03207347 2023-09-15A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)University of FloridaPhase 2 Completed37 enrolled 15 charts